Heart failure & cardiomyopathies
Non-Cardiac Comorbidities and Intensive Up-Titration of Oral Treatment in Patients Recently Hospitalized for Heart Failure: Insights from the STRONG-HF Trial
Authors' conclusion
In the STRONG-HF trial, NCCs neither limited the rapid up-titration of HF therapies, nor attenuated the benefit of HIC on the primary endpoint.
Study context
- Population
- Stable patients recently hospitalized for heart failure (HF) with improved but still elevated natriuretic peptides, classified by NCC number (0, 1, 2, ≥3)
- Participants
- 1,078 participants
- Comparison
- High-intensity care vs usual care, by number of non-cardiac comorbidities
- Primary endpoint
- Death or HF rehospitalization
- Follow-up
- 180 days
Methodological detailssubgroup analysis by NCC number
- Subgroup analysis by NCC number
Primary result
As reported in the abstract
180-day death or HF rehospitalization, by NCC number
0 NCCs
1 NCC
2 NCCs
≥3 NCCs
- Treatment effect high-intensity care (HIC) vs usual care (UC) by NCC number
- interaction-p = 0.80
Further findings
Prevalence of NCC number
- 0 non-cardiac comorbidities (NCCs)
- 24.3%
- 1 NCC
- 39.8%
- 2 NCCs
- 24.5%
- ≥3 NCCs
- 11.4%
Full doses of HF therapies in HIC at 90 and 180 days
- Similar irrespective of NCC number
Quality-of-life improvement, by NCC number
- No significant treatment interaction by NCC number
- P = 0.98
Safety
Serious adverse events, by NCC number
- No significant treatment interaction by NCC number
- P = 0.11
Original publication
Non-Cardiac Comorbidities and Intensive Up-Titration of Oral Treatment in Patients Recently Hospitalized for Heart Failure: Insights from the STRONG-HF Trial. Eur J Heart Fail. Published 4 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →